|
Forecast Period
|
2026-2030
|
|
Market Size (2024)
|
USD 2.05 Billion
|
|
Market Size (2030)
|
USD 3.37 Billion
|
|
CAGR (2025-2030)
|
8.64%
|
|
Fastest Growing Segment
|
Phase III
|
|
Largest Market
|
West India
|
Market Overview
India Clinical Trials Market was valued at USD 2.05 Billion in 2024 and is anticipated to reach USD 3.37 Billion by 2030, with a CAGR of 8.64% during 2025-2030. The Clinical Trials Market refers to the global industry that operates and manages clinical trials, which are crucial research
investigations. In these trials, individuals voluntarily participate to evaluate new treatments, interventions, or tests aimed at preventing, detecting, treating, or managing various diseases or medical conditions. By conducting these trials,
researchers aim to determine not only the safety and effectiveness but also the
scalability of new drugs or treatments, ensuring their potential impact on a
larger scale.
This
market encompasses a wide range of stakeholders, including pharmaceutical
companies, contract research organizations, healthcare providers, academic institutes,
and more. All these entities collaborate in a concerted effort, playing a
pivotal role in accelerating the process of drug discovery and development.
Through their collective endeavors, innovative treatments can be made available
to patients worldwide, addressing unmet medical needs and improving health
outcomes across diverse populations. This continuous pursuit of knowledge and
advancements in clinical research ultimately leads to breakthroughs that shape
the future of medicine and benefit humanity as a whole.
Key Report Takeaway
- Phase III trials led in revenue share, driven by large patient enrollment, long study duration, and high operational costs
- Phase I trials are expected to grow steadily as pharmaceutical and biotechnology firms increase research and development investments
- Interventional trials dominated by study design, supported by strong reliability in evaluating drug safety and treatment effectiveness
- Western India, especially Maharashtra, emerged as a leading hub due to strong research infrastructure, skilled professionals, and diverse patient population
Key Market Drivers
Growing
Demand for Clinical Trials
India is experiencing a steady rise in demand for clinical trials as the healthcare sector increasingly prioritizes evidence-based treatments and validated medical innovations. Clinical trials are essential for assessing the safety and efficacy of new drugs, devices, and therapies before widespread adoption. India’s diverse genetic pool, varied lifestyles, and broad disease spectrum make it an ideal location for comprehensive and inclusive research. Notably, over 2,200 phase-1 trials were registered between 2008 and 2022, reflecting growth in early-stage research capabilities.
The country’s strong research ecosystem, comprising advanced hospitals, specialized institutes, and a skilled medical workforce, continues to attract global pharmaceutical companies. Regulatory improvements under the New Drugs and Clinical Trials Rules, 2019 have streamlined approval timelines and enhanced transparency, boosting international confidence.
Expanding clinical research is also generating economic value through job creation and high-end research services. Companies like Syngene International Limited highlight this growth. With increasing global demand for diverse trial populations, India is poised to play a larger role in advancing medical research and innovation..
High
R&D Expenditure of the Pharmaceutical Industry
Rising investment in research and development by pharmaceutical companies is significantly increasing demand for clinical trials in India because larger innovation pipelines require structured human studies to establish safety, efficacy, dosage, and regulatory acceptability before commercialization. India is well positioned for this activity due to its large and diverse patient pool, relatively cost efficient trial execution, expanding digital regulatory systems, and a clinical research ecosystem supported by trained investigators, hospitals, and global service providers.
The policy environment has also become more attractive under the New Drugs and Clinical Trials Rules 2019, which defined approval timelines of 30 days for drugs discovered in India and 90 days for global clinical trials, improving predictability and reducing procedural uncertainty for sponsors. This stronger framework is helping deepen collaboration across pharmaceutical companies, research institutions, CROs, and care providers, while also supporting high skilled employment and better quality data generation.
For instance, Sun Pharma reported total R and D expenditure of ₹31,775.9 million in FY24 and said its Specialty R and D spend rose to US$148 million with six candidates undergoing clinical trials, clearly showing how rising innovation budgets are translating into greater clinical trial activity in India.
Rising
Prevalence of Diseases
India is witnessing a rapid rise in demand for clinical trials, driven by the increasing prevalence of diseases, particularly chronic conditions such as diabetes and cardiovascular disorders. Changing lifestyles and longer life expectancy have significantly expanded the patient pool, creating an urgent need for new treatments and therapies. Estimates indicate over 100 million people living with diabetes and a large prediabetic population, underscoring the scale of the healthcare burden and the need for continuous clinical research.
India’s diverse genetic makeup offers a strong advantage for conducting inclusive and comprehensive trials, enabling the development of more targeted and personalized therapies. Additionally, the country benefits from a growing base of skilled healthcare professionals and an improving regulatory framework, ensuring high-quality trial execution and adherence to global standards.
The large and diverse population also supports efficient patient recruitment, a key challenge in clinical trials globally. With thousands of registered studies and expanding medical infrastructure, India is strengthening its position as a major hub for clinical research and a key contributor to global healthcare innovation.
Increasing
Research and Development Promoting Outsourcing
The growing demand for clinical trials in India is being driven in large part by rising R and D outsourcing from global pharmaceutical and biotechnology companies, as the country combines cost efficient execution with expanding regulatory support, deep scientific talent, and the scale needed for faster and more representative patient recruitment.
India’s appeal has strengthened further because Invest India states that 94,730 trials have been registered in the country since 2000 and about 18,000 new clinical trials were registered in 2024 alone, reflecting a much larger and more active research base that international sponsors can tap for multicentre and specialty studies.
The country’s broad population diversity and disease burden also improve the value of data generated locally, helping sponsors build evidence that is more relevant for precision therapies, global submissions, and region specific treatment strategies. At the same time, confidence among overseas sponsors has improved as CDSCO has continued digitising approvals through the SUGAM portal and expanded online processing for clinical trial site additions and principal investigator changes, steps that are intended to speed submissions and strengthen oversight.
For instance, IQVIA says it has more than 22,000 employees in India working across clinical research, data management, biostatistics, lifecycle safety, and related functions, and the company also secured CDSCO CRO registration in April 2025, highlighting how major global service providers are expanding regulated execution capacity in India and reinforcing the country’s position as a preferred destination for outsourced clinical development.
Download Free Sample Report
Key Market
Challenges
Lack
of Skilled Workforce in Clinical Research
India’s clinical research sector faces a significant challenge due to the shortage of skilled professionals required to manage complex clinical trials and regulatory processes. Clinical research demands expertise in data analysis, medical protocols, and ethical compliance, yet current academic and training systems are not producing enough qualified talent to meet growing industry needs. This gap slows research activities and limits the efficient execution of large-scale trials.
The shortage also impacts global investment decisions, as international pharmaceutical companies prefer regions with a strong base of trained investigators, data managers, and regulatory experts. Without sufficient talent, India risks missing opportunities to expand its role as a global clinical research hub, despite its advantages in patient diversity and infrastructure.
Addressing this issue requires strengthening education and specialized training programs in clinical research. Greater collaboration between academia and industry, along with increased awareness of career opportunities, can help build a robust talent pipeline. Expanding the skilled workforce will enhance research capacity, attract global investment, and support India’s long-term growth in clinical development.
Stringent
Regulations for Patient Enrollment
Strict patient enrollment requirements remain a meaningful challenge for clinical trials in India because eligibility rules linked to age, disease status, prior treatment history, and overall medical profile are designed to protect participants and preserve scientific validity, but they also narrow the recruitable pool at the site level.
The process becomes more demanding because informed consent must be obtained only after participants are fully briefed on trial procedures, potential risks, and expected benefits, and published assessments of India’s regulatory framework note that requirements such as audio visual recording of consent in certain situations can add further operational complexity.
These safeguards are important for ethics and data integrity, yet they can lengthen screening cycles when potential volunteers hesitate over invasive procedures, time commitment, travel burden, or safety concerns, and an investigator survey in India found that complexity of study protocol was cited by 38 percent of respondents, while lack of patient awareness and sociocultural issues were each cited by 37 percent as key recruitment barriers. Delays in enrollment ultimately raise study timelines and costs for sponsors, which is one reason patient recruitment remains a decisive execution issue even in a country with strong research capabilities.
For instance, ICON says it has over 4,500 professionals in India across Chennai, Bangalore, Trivandrum, and more than 18 states, showing that even large clinical development organizations with broad local reach still operate in an environment where careful patient protection must be balanced against faster and more efficient enrollment.
Key Market Trends
Adoption
Of New Technology in Clinical Research
The adoption of new technology is materially increasing demand for clinical trials in India because digital platforms, AI enabled workflows, and more automated regulatory processes are helping sponsors run studies with better speed, accuracy, and operational control across increasingly complex protocols.
India has become more attractive for global pharmaceutical companies and CROs as this shift combines with the country’s large and diverse patient base, and Invest India notes that 94,730 trials have been registered since 2000, with about 18,000 new clinical trials registered in 2024 alone, underlining how rapidly the research ecosystem is scaling.
The regulatory environment is also becoming more technology driven, with CDSCO requiring all clinical trial applications for cell and gene therapeutic products to move to the SUGAM online portal from July 10 2025, a step that supports faster and more standardized submissions. Digital execution is further strengthening patient centricity and decentralized trial models, since ICON says its Digital Platform supports integrated decentralized clinical trials and includes a global translation framework with more than 17 validated languages to help speed patient services and regulatory processes.
Digitalization
Of Clinical Trials
The
digitalization of clinical trials is expected to have a positive and
transformative impact on market growth. With the advancement of digital
technologies, multiple trial processes such as data capture, regulatory
compliance, logistics and supplies management, and more, have been streamlined,
leading to increased efficiency and effectiveness. This digital revolution has
revolutionized the way clinical trials are conducted, allowing for real-time
data acquisition related to safety and toxicity. The ability to rectify any
issues promptly in trial design has further facilitated market growth.
In
addition to the numerous benefits of digitalization, it is worth noting that
the cost of clinical trials in India is nearly half of that incurred in the
U.S. and Europe. This significant cost efficiency not only attracts global
pharmaceutical companies but also creates a favorable environment for
conducting clinical trials within the country. India offers a
large treatment-naïve patient pool, which is highly valuable for conducting
rigorous and diverse clinical studies. These factors, combined, contribute to
the overall growth of the market and position India as a prominent destination
for clinical research and development.
Segmental Insights
Phase Insights
Based on the phase,
the phase III segment emerged as the leader in terms of revenue share.
This can be attributed to the inherently cost-intensive nature of this phase.
Phase III trials necessitate a substantial patient population, which is one of
the primary reasons for the high cost associated with conducting these trials. The studies conducted in this phase typically span over several
years, unlike phase I and II, which contributes to the overall cost of the
trial and further bolsters the segment's dominance in the market.
On the other
hand, the phase I segment is expected to witness notable growth over the
forecast period, mainly due to the substantial research and development
(R&D) investments made by both global and local pharmaceutical and
biotechnological firms. The increasing demand for novel treatments and
biologics, driven by advancements in medical science and the growing healthcare
needs, further fuels the growth of this segment. When it comes to the different
phases of clinical trials, the market is divided into phase I, phase II, phase
III, and phase IV. Each phase plays a crucial role in the drug development
process.
Phase I primarily focuses on initial safety testing, phase II assesses
the effectiveness of the treatment, phase III evaluates the treatment's
efficacy and safety on a larger scale, and phase IV monitors the drug's
long-term effects after it has been approved and released to the market. The
continuous advancements and innovations in the field of clinical trials
contribute to the overall growth and development of the healthcare industry,
ensuring the availability of safe and effective treatments for patients
worldwide.
Study Design Insights
Based on study
design, the interventional trials segment held the largest revenue share, primarily driven by the adoption of this study design in a large number
of trials. This type of study design, which includes large randomized clinical
trials, is widely recognized as one of the most effective approaches for detecting
small to moderate effects of drugs. It offers robust means of
minimizing the influence of confounding variables, further enhancing its appeal
compared to other clinical study designs.
On the other
hand, the expanded access trials segment is expected to witness a significant
compound annual growth rate (CAGR) during the forecast period. This can be
attributed to various factors, including the rising prevalence of serious
diseases, the increasing demand for innovative treatment options, and the
substantial burden of chronic diseases in the country. These factors
collectively contribute to the growth of the expanded access trials segment,
offering greater opportunities for patients to access novel therapies and
interventions.
Download Free Sample Report
Regional Insights
The
Western region of India is emerging as a dominant force in the India Clinical
Trials Market. With its well-established and state-of-the-art infrastructure
for clinical research, including cutting-edge medical facilities and advanced
laboratories, the region offers a highly conducive and progressive environment
for conducting a wide range of clinical trials.
Maharashtra
boasts a pool of experienced professionals in the field who possess in-depth knowledge
and expertise in various therapeutic areas. These professionals are supported
by a robust network of research institutions and academic centers, fostering
collaboration and innovation in the field of clinical research. The state of Maharashtra has a high patient population, comprising diverse
demographics and a mix of urban and rural communities.
This provides ample
opportunities for recruitment and participation in clinical trials, ensuring a
comprehensive representation of the target population and enhancing the
generalizability of study results. As a result of these favorable factors and
conducive ecosystem, Maharashtra has become the preferred destination for both
domestic and international organizations looking to conduct diverse and
impactful clinical trials in the country. The state's commitment to ethical
practices, regulatory compliance, and patient safety further strengthens its
position as a leading hub for clinical research in India.
Recent Developments
- In September 2025, Roche Pharma India announced the completion of the first phase of its Advanced Inclusive Research Site Alliance initiative after partnering with 10 government hospitals across the country. The company said the program trained nearly 400 investigators, ethics committee members, and support staff to global Good Clinical Practice standards, while also improving digital readiness and operational efficiency at participating sites. This was a significant collaboration for India clinical trials because it aimed to expand high-quality trial capacity in public hospitals, where patient diversity is high but research infrastructure has often lagged.
- In November 2025, Tata Consultancy Services launched the next generation of its AI-powered TCS ADD Risk Based Quality Management platform for clinical trials. TCS said the upgraded platform provides analytics-led oversight across the trial lifecycle and helps stakeholders identify risks earlier, improve protocol compliance, and strengthen quality management in complex studies. For India’s clinical trials landscape, the launch stood out as a breakthrough innovation because it signaled stronger domestic capability in digital trial infrastructure, an area becoming central to faster and more scalable clinical research.
- In November 2025, Tata Consultancy Services launched the next generation of the TCS ADD Risk Based Quality Management platform, adding AI-powered modules for risk assessment, trial analytics, quality tolerance limits, and patient-level data monitoring across the clinical-trial lifecycle.
Key Market Players
|
By Phase
|
By Study Design
|
By Indication
|
By Region
|
- Phase I
- Phase II
- Phase III
- Phase IV
|
- Interventional
- Observational
- Expanded Access
|
- Autoimmune
- Blood Disorders
- Pain Management
- Oncology
- CNS Condition
- Diabetes
- Obesity
- Cardiovascular
- Others
|
- North India
- East India
- West India
- South India
|
Report
Scope:
In
this report, the India Clinical Trials Market has been segmented into the following
categories, in addition to the industry trends which have also been detailed
below:
- India Clinical Trials Market, By Phase:
o
Phase I
o
Phase II
o
Phase III
o
Phase IV
- India Clinical Trials Market, By Study Design:
o
Interventional
o
Observational
o
Expanded Access
- India Clinical Trials Market, By Indication:
o
Autoimmune
o
Blood Disorders
o
Pain Management
o
Oncology
o
CNS Condition
o
Diabetes
o
Obesity
o
Cardiovascular
o
Others
- India Clinical Trials Market, By Region:
o
North
o
South
o
West
o
East
Competitive
Landscape
Company
Profiles: Detailed
analysis of the major companies present in the India Clinical Trials Market.
Available
Customizations:
India
Clinical Trials Market report with the given market data, Tech Sci
Research offers customizations according to a company's specific needs. The
following customization options are available for the report:
Company
Information
- Detailed analysis and profiling of
additional market players (up to five).
India Clinical Trials
Market is an upcoming report to be released soon. If you wish an early delivery
of this report or want to confirm the date of release, please contact us at [email protected]